ALXO vs. HRMY
ALXO (ALX Oncology Holdings Inc.) and HRMY (Harmony Biosciences Holdings, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, ALXO returned -49.41%/yr vs 6.14%/yr for HRMY. Their 0.23 correlation means their historical movements had little consistent relationship.
Performance
ALXO vs. HRMY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ALXO achieves a 71.68% return, which is significantly higher than HRMY's -5.83% return.
ALXO
- 1D
- -0.51%
- 1M
- -6.28%
- 6M
- 11.49%
- YTD
- 71.68%
- 1Y
- 274.45%
- 3Y*
- -31.21%
- 5Y*
- -49.41%
- 10Y*
- —
- ALL TIME*
- -38.50%
HRMY
- 1D
- -1.73%
- 1M
- -5.42%
- 6M
- -3.50%
- YTD
- -5.83%
- 1Y
- 2.44%
- 3Y*
- 1.21%
- 5Y*
- 6.14%
- 10Y*
- —
- ALL TIME*
- -2.10%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $1.10M | $1.73M | $2.41M | |
| $30.21M | $30.03M | $28.08M |
ALXO vs. HRMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
ALXO ALX Oncology Holdings Inc. | 71.68% | -32.34% | -88.78% | 32.12% | -47.56% | -75.07% | 101.17% |
HRMY Harmony Biosciences Holdings, Inc. | -5.83% | 8.75% | 6.53% | -41.38% | 29.22% | 17.95% | -9.60% |
Correlation
The correlation between ALXO and HRMY is 0.10, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.10 |
Correlation (3Y) Balances recent behavior with more history. | 0.15 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.24 |
Correlation (All Time) Calculated using the full available price history since Aug 19, 2020 | 0.23 |
The correlation between ALXO and HRMY shifts across timeframes, from 0.10 (1 year) to 0.24 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
ALXO:
$261.05M
HRMY:
$2.04B
ALXO:
-$1.25
HRMY:
$2.48
ALXO:
1.34
HRMY:
2.28
ALXO:
$0.00
HRMY:
$899.11M
ALXO:
$0.00
HRMY:
$688.25M
ALXO:
-$88.92M
HRMY:
$221.74M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ALXO vs. HRMY — Risk / Return Rank
ALXO
HRMY
ALXO vs. HRMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ALX Oncology Holdings Inc. (ALXO) and Harmony Biosciences Holdings, Inc. (HRMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ALXO | HRMY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.10 | ||
| Sortino ratioReturn per unit of downside risk | +2.62 | ||
| Omega ratioGain probability vs. loss probability | 1.33 | 1.04 | +0.29 |
| Calmar ratioReturn relative to maximum drawdown | 4.83 | 0.01 | +4.82 |
| Martin ratioReturn relative to average drawdown | 9.03 | 0.01 | +9.03 |
Loading charts...
Drawdowns
ALXO vs. HRMY - Drawdown Comparison
The maximum ALXO drawdown since its inception was -99.64%, which is greater than HRMY's maximum drawdown of -68.48%. Use the drawdown chart below to compare losses from any high point for ALXO and HRMY.
Loading charts...
Drawdown Indicators
| ALXO | HRMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.64% | -68.48% | -31.16% |
Max Drawdown (1Y)Largest decline over 1 year | -50.46% | -34.49% | -15.97% |
Max Drawdown (3Y)Largest decline over 3 years | -97.69% | -50.81% | -46.88% |
Max Drawdown (5Y)Largest decline over 5 years | -99.50% | -68.48% | -31.02% |
Current DrawdownCurrent decline from peak | -98.27% | -42.14% | -56.13% |
Average DrawdownAverage peak-to-trough decline | -79.69% | -35.42% | -44.27% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 26.91% | 19.24% | +7.67% |
Volatility
ALXO vs. HRMY - Volatility Comparison
ALX Oncology Holdings Inc. (ALXO) has a higher volatility of 21.75% compared to Harmony Biosciences Holdings, Inc. (HRMY) at 14.79%. This indicates that ALXO's price experiences larger fluctuations and is considered to be riskier than HRMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ALXO | HRMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 21.75% | 14.79% | +6.96% |
Volatility (6M)Calculated over the trailing 6-month period | 58.88% | 32.46% | +26.42% |
Volatility (1Y)Calculated over the trailing 1-year period | 115.83% | 43.31% | +72.52% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 100.05% | 50.15% | +49.90% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 98.51% | 52.28% | +46.23% |
Dividends
ALXO vs. HRMY - Dividend Comparison
Neither ALXO nor HRMY has paid dividends to shareholders.
Financials
ALXO vs. HRMY - Financials Comparison
This section allows you to compare key financial metrics between ALX Oncology Holdings Inc. and Harmony Biosciences Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ALXO and HRMY have a correlation of 0.10, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ALXO has higher volatility (21.75%) compared to HRMY (14.79%). In terms of maximum drawdown, ALXO dropped -99.64% vs HRMY's -68.48%.
ALXO currently has the higher Sharpe Ratio (2.10 vs 0.00), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ALXO and HRMY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer